CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

tucatinib

Last Updated: March 29, 2021
Result type: Reports
Project Number: PC0243-000
Product Line: Reimbursement Review

Generic Name: tucatinib

Brand Name: Tukysa

Manufacturer: Seagen Canada Inc.

Therapeutic Area: Advanced or Metastatic Breast Cancer

Indications: ​Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.

Manufacturer Requested Reimbursement Criteria1: In combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.

Submission Type: Initial

Tumour Type: Breast

NOC Status at Filing: Post NOC

Project Status: Received

Companion Diagnostics: No

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openFebruary 26, 2021
Call for patient/clinician input closedApril 23, 2021
Submission receivedMarch 26, 2021
Submission accepted-
Submit Feedback